Sphingolipids Market Will Generate Booming Growth Opportunities to 2032

As per Future Market Insights’ latest industry analysis, the valuation for the global sphingolipids market was around US$ 564.0 Mn in 2021 and is projected to exhibit a CAGR growth of close to 5.1% over the forecast period, with an estimated valuation of US$ 991.8 Mn in 2032.

The global market for sphingolipid products is expanding rapidly as a result of rapid molecular and biological customization in the sphingolipid components/ formulations and the increasing prevalence of cardiovascular diseases worldwide coupled with an elderly population.  During the forecast period, the market is anticipated to be driven by an increase in the use of natural, synthetic, and semi-synthetic sphingolipids and monomers in the creation of various pharmaceutical formulations.

As the sphingolipids market is not reaching its potential as per the asked demand, due to unexplored benefits of sphingolipids in the healthcare sector, and the side effects of the consumption of sphingolipids inappropriately, the companies are introducing novel sphingolipids components/formulations with minimal side effects at reasonable costs.

This factor might significantly improve the adoption and consumption of pharmaceutical sphingolipids. The rising product launches and approvals are expected to contribute to the market growth over the forecast period too.

Key Takeaways from Market Study

  • Sphingomyelin is the leading segment as a product and holds approximately 0% market share in 2021, due to its anti-cancer, bacteriostatic, and cholesterol-lowering characteristics.
  • Synthetic sphingolipids are the leading segment by source, and held about 4% market share in 2021, owing to their potential as therapeutic prospects for treating a range of medical problems.
  • Conventional lipid-based drug delivery systems (LBDDS) is the leading segment in terms of application holding about 9% of the market share, as compared to traditional tablets or powder-filled capsules, as they can improve bioavailability and reduce dissolving rate-limited absorption because of their pharmacological composition in a solubilized condition.
  • Semi-solid form of sphingolipids is the leading form as of 2021, withholding about 3% of the global market share, owing to the property of reduced adverse side effects when a high drug load is applied to the area where the medication is actually required.
  • Pharmaceutical companies are the leading end users of the global market as of 2021, withholding about 5% of the market share, because of increased outsourcing, innovative modalities, and creative patient outreach tactics.
  • By region, North America is leading in the global sphingolipids market and is expected to continue to do so with a projected CAGR of 4% during the forecasted years.

“Rising initiatives to promote health benefits of sphingolipids products, as well as the increasing ongoing research and development in modifying novel sphingolipids formulations is set to propel the market of sphingolipids across the globe,” says an analyst of Future Market Insights.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15713

Market Competition

Companies are actively working to increase their market share in this industry by forming strategic agreements to diversify their respective service offerings and sphingolipid production capacities.

  • In January 2022, Pfizer and Acuitas Therapeutics reached an agreement on Lipid Nanoparticle Delivery System for mRNA vaccines and therapeutics.
  • June 2022: To support customers' scientific research, CD Bioparticles, enlarged its lipid system portfolio and introduced a number of Sphingolipids products. With the addition of Phosphosphingolipids, Ceramides, Sphingolipid Metabolism, Sphingosines, Glycosphingolipids, Phytosphingosine, and Sphingomyelin, researchers now have more options to choose from and employ in lipid system applications.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the sphingolipids market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032.

The research study is based on the product (ceramide, sphingomyelin, glucosylceramide (GlcCer), lactosylceramide (LacCer), ganglioside GM3, and Other), source (synthetic, semi-synthetic, and natural), application (conventional lipid-based drug delivery systems (LBDDS), self-emulsifying drug delivery systems (SEDDS), self-micro emulsifying drug delivery systems (SMEDDS), liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and others), form (liquid, semi-solid, and solid), and end user (pharmaceutical companies, biopharmaceutical companies, academics, and research institutes, and others), across seven key regions of the world.

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here.

Key Segments Covered In Sphingolipids Industry Research

By Product:

  • Ceramide
  • Sphingomyelin
  • Glucosylceramide (GlcCer)
  • Lactosylceramide (LacCer)
  • Ganglioside GM3
  • Other

By Source:

  • Synthetic
  • Semi-synthetic
  • Natural

By Application:

  • Conventional Lipid-based Drug Delivery Systems (LBDDS)
  • Self-Emulsifying Drug Delivery Systems (SEDDS)
  • Self-Microemulsifying Drug Delivery Systems (SMEDDS)
  • Liposomes
  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers
  • Others

By Form:

  • Liquid
  • Semi-solid
  • Solid

By End User:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Academics and Research Institutes
  • Others

Comments

Post a Comment

Popular posts from this blog

Mammography Market Demand, Scope and Future Estimation until 2032

  The global  mammography market    is estimated to be worth around  US$ 1.7 Billion  in 2022. However, with rising prevalence of breast cancer at an alarming rate the overall demand for mammography systems is anticipated to grow at around  6.5%  to  9% CAGR  between 2022 and 2032, totaling over  US$ 3.4 Billion  by 2032. Mammography  is a modern non-invasive medical imaging and diagnostic technique that uses low-dose X-rays to monitor breast tissues for the presence of tumor. It has become one of the most commonly used techniques for checking abnormalities in the absence of any symptoms. It has significantly aided in reducing breast cancer mortality rates worldwide. Increasing prevalence of breast cancer across the world along with growing awareness about the benefits of screening and early diagnosis of breast cancer is providing a major impetus to the growth of mammography market. It is one of the most common forms of cancer among females, worldwide. Various studies have found that t
Read more

Interventional Cardiology Devices Market Key Players, SWOT Analysis, Key Indicators & Forecast By 2032

  The  interventional cardiology devices market demand  is expected to grow at an  8.4%  CAGR from  USD 16.4  Billion in 2022 to USD  36.9  Billion by 2032. The fast expansion of the geriatric population and the corresponding increase in the prevalence of coronary artery diseases, the approval of new and sophisticated products, and the growing incidence of diabetes are all driving growth in the interventional cardiology devices market. However, the availability of alternative therapies, as well as product failures and recalls, are the primary factors projected to hinder interventional cardiology devices market growth over the projection period. COVID-19 has had a global influence on every element of the medical device business, including the market for interventional cardiology equipment. Despite the fact that emergency and outpatient treatments are offered in cardiology departments, the number of patient visits to hospitals has decreased dramatically in the last six months. Patient vi
Read more

Cardiac Rehabilitation Market Research, Segmentation, Key Players Analysis & Forecast By 2032

  The  cardiac rehabilitation market share  is likely to expand its roots in the global market at an average CAGR of 6.0% between 2022 and 2032. The market is valued at US$ 2.1 Bn in 2022 and is likely to reach US$ 3.8 Bn by 2032. Previously, the market was thriving at a slightly higher CAGR of 6.5% (2015-2021), ensuring a market size of US$ 2 Billion in 2021. “Growing lifestyle-related diseases like diabetes and cardiovascular strokes along with the technological revolution in the healthcare sector, helping the patients going through heart attack, heart valve surgeries, heart failures.” An unhealthy lifestyle is leading to new heart-related diseases like heart attacks and heart failure. The technologically advanced tools that enable easy surgery processes drive the sales of cardiac rehabilitation systems. These systems help end users with exercises, diet, stress management and training, managing and monitoring the daily progress of the health routine. It is largely consumed by The new
Read more